Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug approval

Amneal Lanreotide Generic FDA Approval Launch

Analysis based on 10 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
5
Attention
2
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval gives Amneal a new revenue driver in a roughly $983 million U.S. market and pressures Ipsen's branded Somatuline franchise as generic competition enters. Investor reaction was modestly positive, with AMRX rising 2.35% on the announcement.

pharmaceuticals biotechnology healthcare

Amneal Pharmaceuticals received U.S. United States — Food and Drug Administration approval for its lanreotide injection, 120 mg/0.5 mL, a generic version of Somatuline Depot, and launched the product immediately. The approval carries Competitive Generic Therapy designation. Lanreotide is indicated for acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. Somatuline Depot, originally developed by Ipsen, had U.S. annual sales of $983 million for the 12 months ended July 2026 according to IQVIA. Amneal will produce the drug in-house with dedicated large-scale manufacturing capacity. AMRX shares closed up 2.35% at $18.71 on the news.

80 Amneal Pharmaceuticals launched lanreotide injection
stock
Amneal secured FDA approval and immediate launch of generic lanreotide, adding a material growth driver to its complex injectables portfolio and lifting its shares 2.35%.
Importance 95.0 Sentiment 60.0
govactor
The FDA approved Amneal's lanreotide injection and granted Competitive Generic Therapy designation, enabling immediate generic competition.
Importance 60.0 Sentiment 0.0
stock
Ipsen's branded Somatuline Depot, with $983 million in U.S. annual sales, now faces generic competition from Amneal's approved lanreotide injection.
Importance 40.0 Sentiment -30.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.